Eye drops for dry eye in early neurotrophic keratopathy
Part of Eyes & vision clinical trials.
This trial tests a new eye drop (acoltrepon) to see if it helps people with stage 1 neurotrophic keratopathy (a condition where the cornea's nerves are damaged, causing dry eyes and vision problems) and low tear production. It aims to improve signs like corneal staining and symptoms of discomfort.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage 1 neurotrophic keratopathy (with decreased corneal sensation and staining on the eye exam).
- Your tear production is low (Schirmer test score of 10 mm or less).
- You can stop other eye drops 8 days before starting the study and artificial tears 2 hours before visits.
- You have no active eye infection, inflammation, or corneal ulcers/scars.
- You've had no eye surgery in the last 3 months and don't plan any during the study.
- You are not pregnant, breastfeeding, or planning pregnancy, and if female of childbearing potential, you'll have a negative pregnancy test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new eye drop (acoltre mon) to see if it helps people who have both dry eyes and nerve-related eye pain. The drops may increase tear production and reduce burning or light sensitivity.
This trial tests whether a new eye drop called Lacripep can help treat neurotrophic keratitis, a rare eye condition where the cornea loses sensation and can become damaged. The study compares Lacripep to a placebo (inactive) drop to see if it improves corneal healing and vision.
This study tests a new treatment for dry eye disease caused by Sjögren's syndrome. It may help people who still have dry eye symptoms even when using artificial tears.
This study tests a new eye drop called Acoltremon to see if it can relieve symptoms of moderate-to-severe dry eye disease. It may be a good option if you have had dry eye for at least 6 months and use artificial tears.
This trial tests an experimental eye drop (STSP-0902) for a condition called neurotrophic keratitis, where the cornea (the clear front part of the eye) gets scratches or sores because nerves are damaged. The drop contains a growth factor to help the eye heal. You might be eligible if you have a persistent scratch or sore on your cornea that has not improved for at least a week.
This trial studies an FDA-approved eye drop called acoltremon for treating dry eye disease. The goal is to see how well it works in everyday life, using patient surveys to measure symptom improvement.
Hear when a new Ocular Surface Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.